{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:43:50Z","timestamp":1760784230536},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13023-017-0592-6","type":"journal-article","created":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T12:47:06Z","timestamp":1487594826000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A new framework for evaluating the health impacts of treatment for Gaucher disease type 1"],"prefix":"10.1186","volume":"12","author":[{"given":"Michael L.","family":"Ganz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luba","family":"Nalysnyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Selzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,2,20]]},"reference":[{"key":"592_CR1","doi-asserted-by":"publisher","unstructured":"Rosenbloom BE, Weinreb NJ. Gaucher disease: a comprehensive review. Crit Rev Oncog. 2013;18:163\u201375. doi: 10.1615\/CritRevOncog.2013006060 .","DOI":"10.1615\/CritRevOncog.2013006060"},{"key":"592_CR2","doi-asserted-by":"publisher","unstructured":"Burrow TA, Barnes S, Grabowski GA. Prevalence and management of Gaucher disease. Pediatric Health Med Ther. 2011;2:59\u201373. doi: 10.2147\/PHMT.S12499 .","DOI":"10.2147\/PHMT.S12499"},{"issue":"9","key":"592_CR3","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/1060028013500469","volume":"47","author":"LL Bennett","year":"2013","unstructured":"Bennett LL, Mohan D. Gaucher disease and its treatment options. Ann Pharmacother. 2013;47(9):1182\u201393. doi: 10.1177\/1060028013500469 .","journal-title":"Ann Pharmacother"},{"key":"592_CR4","doi-asserted-by":"publisher","unstructured":"Deegan PB, Batista J. Risk factors for fracture in imiglucerase-treated Gaucher disease type 1 patients in the ICGG Gaucher Registry. Mol Genet Metab. 2016;117(2):S40. doi: 10.1016\/j.ymgme.2015.12.237 .","DOI":"10.1016\/j.ymgme.2015.12.237"},{"key":"592_CR5","volume-title":"The online metabolic and molecular bases of inherited disease","author":"GA Grabowski","year":"2007","unstructured":"Grabowski GA, Petsko GA, Kolodny EH. Gaucher disease. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson KM, Mitchel G, editor. The online metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2007. Chapter 146."},{"issue":"4 Suppl","key":"592_CR6","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jpeds.2009.07.004","volume":"155","author":"AM Martins","year":"2009","unstructured":"Martins AM, Valadares ER, Porta G, Coelho J, Semionato Filho J, Pianovski MA, Kerstenetzky MS, Montoril Mde F, Aranda PC, Pires RF, et al. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr. 2009;155(4 Suppl):S10\u201318. doi: 10.1016\/j.jpeds.2009.07.004 .","journal-title":"J Pediatr"},{"issue":"2","key":"592_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ymgme.2015.09.002","volume":"117","author":"M Balwani","year":"2016","unstructured":"Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, Mistry P, Ruskin J, Weinreb N. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 2016;117(2):95\u2013103. doi: 10.1016\/j.ymgme.2015.09.002 .","journal-title":"Mol Genet Metab"},{"key":"592_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1750-1172-9-51","volume":"9","author":"L Dussen van","year":"2014","unstructured":"van Dussen L, Biegstraaten M, Hollak CE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis. 2014;9:51. doi: 10.1186\/1750-1172-9-51 .","journal-title":"Orphanet J Rare Dis"},{"key":"592_CR9","doi-asserted-by":"publisher","unstructured":"Ficicioglu C. Review of miglustat for clinical management in Gaucher disease type 1. Ther Clin Risk Manag. 2008;4(2):425\u201331. doi: 10.2147\/TCRM.S6865 .","DOI":"10.2147\/TCRM.S6865"},{"key":"592_CR10","unstructured":"Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review. Health Technol Assess. 2006;10(24):iii-iv, ix-136. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK62295 . Accessed 13 Feb 2017."},{"issue":"1","key":"592_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/GIM.0b013e3181c39194","volume":"12","author":"NJ Weinreb","year":"2010","unstructured":"Weinreb NJ, Cappellini MD, Cox TM, Giannini EH, Grabowski GA, Hwu WL, Mankin H, Martins AM, Sawyer C, vom Dahl S, et al. A validated disease severity scoring system for adults with type 1 Gaucher disease. Genet Med. 2010;12(1):44\u201351. doi: 10.1097\/GIM.0b013e3181c39194 .","journal-title":"Genet Med"},{"key":"592_CR12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","volume":"10","author":"NJ Weinreb","year":"2015","unstructured":"Weinreb NJ, Finegold DN, Feingold E, Zeng Z, Rosenbloom BE, Shankar SP, Amato D. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3). Orphanet J Rare Dis. 2015;10:64. doi: 10.1186\/s13023-015-0280-3 .","journal-title":"Orphanet J Rare Dis"},{"key":"592_CR13","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2880930 . Accessed 13 Feb 2017."},{"issue":"8659","key":"592_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0140-6736(89)90536-9","volume":"334","author":"A Zimran","year":"1989","unstructured":"Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E. Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet. 1989;334(8659):349\u201352. doi: 10.1016\/S0140-6736(89)90536-9 .","journal-title":"Lancet"},{"key":"592_CR15","volume-title":"SF-36 health survey: manual and interpretation guide","author":"JE Ware","year":"1993","unstructured":"Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center Hospital; 1993."},{"issue":"1","key":"592_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53\u201372. doi: 10.1016\/0168-8510(96)00822-6 .","journal-title":"Health Policy"},{"key":"592_CR17","doi-asserted-by":"crossref","unstructured":"Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42(9):851\u20139. http:\/\/www.jstor.org\/stable\/4640827 . Accessed 13 Feb 2017.","DOI":"10.1097\/01.mlr.0000135827.18610.0d"},{"issue":"1","key":"592_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1475-6773.2008.00900.x","volume":"44","author":"LC Kleinman","year":"2009","unstructured":"Kleinman LC, Norton EC. What\u2019s the risk? a simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. Health Serv Res. 2009;44(1):288\u2013302. doi: 10.1111\/j.1475-6773.2008.00900.x .","journal-title":"Health Serv Res"},{"issue":"3","key":"592_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","volume":"36","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C. Long-term clinical outcomes in type 1 Gaucher disease following 10\u00a0years of imiglucerase treatment. J Inherit Metab Dis. 2013;36(3):543\u201353. doi: 10.1007\/s10545-012-9528-4 .","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"592_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ajh.24040","volume":"90","author":"A Zimran","year":"2015","unstructured":"Zimran A, Wang N, Ogg C, Crombez E, Cohn GM, Elstein D. Seven-year safety and efficacy with velaglucerase alfa for treatment-naive adult patients with type 1 Gaucher disease. Am J Hematol. 2015;90(7):577\u201383. doi: 10.1002\/ajh.24040 .","journal-title":"Am J Hematol"},{"key":"592_CR21","doi-asserted-by":"publisher","unstructured":"Weinreb NJ, Rosenbloom BE. Splenomegaly, hypersplenism, and hereditary disorders with splenomegaly. Open J Genetics. 2013;3:24\u201343. doi: 10.4236\/ojgen.2013.31004 .","DOI":"10.4236\/ojgen.2013.31004"},{"issue":"12","key":"592_CR22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/ajh.21305","volume":"83","author":"NJ Weinreb","year":"2008","unstructured":"Weinreb NJ, Deegan P, Kacena KA, Mistry P, Pastores GM, Velentgas P, vom Dahl S. Life expectancy in Gaucher disease type 1. Am J Hematol. 2008;83(12):896\u2013900. doi: 10.1002\/ajh.21305 .","journal-title":"Am J Hematol"},{"issue":"7","key":"592_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jama.2015.459","volume":"313","author":"PK Mistry","year":"2015","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, Ghosn M, Mehta A, Packman S, Pastores G, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313(7):695\u2013706. doi: 10.1001\/jama.2015.459 .","journal-title":"JAMA"},{"key":"592_CR24","doi-asserted-by":"crossref","unstructured":"Giraldo P, Solano V, Perez-Calvo JI, Giralt M, Rubio-Felix D. Spanish group on gaucher d. Quality of life related to type 1 gaucher disease: Spanish experience. Qual Life Res. 2005;14(2):453\u201362. http:\/\/www.jstor.org\/stable\/4038778 . Accessed 13 Feb 2017.","DOI":"10.1007\/s11136-004-0794-y"},{"issue":"6","key":"592_CR25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","volume":"71","author":"N Weinreb","year":"2007","unstructured":"Weinreb N, Barranger J, Packman S, Prakash-Cheng A, Rosenbloom B, Sims K, Angell J, Skrinar A, Pastores GM. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of gaucher disease. Clin Genet. 2007;71(6):576\u201388. doi: 10.1111\/j.1399-0004.2007.00811.x .","journal-title":"Clin Genet"},{"key":"592_CR26","volume-title":"Self-reported population health: an international perspective based on EQ-5D","author":"B Janssen","year":"2013","unstructured":"Janssen B, Szende A. Population norms for the EQ-5D. In: Szende A, Janssen B, Cabases J, editor. Self-reported population health: an international perspective based on EQ-5D. Dordrecht: Springer Netherlands; 2013."},{"issue":"Suppl 1","key":"592_CR27","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1002\/ajh.24056","volume":"90","author":"J Charrow","year":"2015","unstructured":"Charrow J, Scott CR. Long-term treatment outcomes in Gaucher disease. Am J Hematol. 2015;90 Suppl 1:S19\u201324. doi: 10.1002\/ajh.24056 .","journal-title":"Am J Hematol"},{"issue":"1","key":"592_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","volume":"90","author":"PB Deegan","year":"2011","unstructured":"Deegan PB, Pavlova E, Tindall J, Stein PE, Bearcroft P, Mehta A, Hughes D, Wraith JE, Cox TM. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy. Medicine (Baltimore). 2011;90(1):52\u201360. doi: 10.1097\/MD.0b013e3182057be4 .","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"592_CR29","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s10545-014-9680-0","volume":"37","author":"LJ Anderson","year":"2014","unstructured":"Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Hughes DA, Waldek S, Logan S. Long-term effectiveness of enzyme replacement therapy in adults with Gaucher disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. 2014;37(6):953\u201360. doi: 10.1007\/s10545-014-9680-0 .","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"592_CR30","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10545-014-9693-8","volume":"37","author":"LJ Anderson","year":"2014","unstructured":"Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek S, Hughes DA, Pastores GM, Logan S. Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. 2014;37(6):961\u20138. doi: 10.1007\/s10545-014-9693-8 .","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"592_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.beem.2014.08.006","volume":"29","author":"CE Hollak","year":"2015","unstructured":"Hollak CE, Weinreb NJ. The attenuated\/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease. Best Pract Res Clin Endocrinol Metab. 2015;29(2):205\u201318. doi: 10.1016\/j.beem.2014.08.006 .","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"592_CR32","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajh.21280","volume":"83","author":"N Weinreb","year":"2008","unstructured":"Weinreb N, Taylor J, Cox T, Yee J, vom Dahl S. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol. 2008;83(12):890\u20135. doi: 10.1002\/ajh.21280 .","journal-title":"Am J Hematol"},{"issue":"8","key":"592_CR33","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.3324\/haematol.12379","volume":"93","author":"M Rocco Di","year":"2008","unstructured":"Di Rocco M, Giona F, Carubbi F, Linari S, Minichilli F, Brady RO, Mariani G, Cappellini MD. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica. 2008;93(8):1211\u20138. doi: 10.3324\/haematol.12379 .","journal-title":"Haematologica"},{"key":"592_CR34","unstructured":"Burrow TA, Balwani M, Cox TM, Drelichman G, Cravo R, Martins AM, Lukina E, Rosenbloom BE, Ross LH, Angell J, Puga AC. ENCORE: A randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic goals. Blood. 2013;122(21):3468. http:\/\/www.bloodjournal.org\/content\/122\/21\/3468 . Accessed 13 Feb 2017."},{"issue":"9985","key":"592_CR35","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0140-6736(14)61841-9","volume":"385","author":"TM Cox","year":"2015","unstructured":"Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC. Eliglustat compared with imiglucerase in patients with Gaucher\u2019s disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385(9985):2355\u201362. doi: 10.1016\/S0140-6736(14)61841-9 .","journal-title":"Lancet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-017-0592-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T16:07:17Z","timestamp":1589731637000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-017-0592-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,20]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["592"],"URL":"https:\/\/doi.org\/10.1186\/s13023-017-0592-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,20]]},"article-number":"38"}}